JP3391796B2 - 新規化合物、その製法および抗腫瘍剤 - Google Patents

新規化合物、その製法および抗腫瘍剤

Info

Publication number
JP3391796B2
JP3391796B2 JP50192396A JP50192396A JP3391796B2 JP 3391796 B2 JP3391796 B2 JP 3391796B2 JP 50192396 A JP50192396 A JP 50192396A JP 50192396 A JP50192396 A JP 50192396A JP 3391796 B2 JP3391796 B2 JP 3391796B2
Authority
JP
Japan
Prior art keywords
group
compound
hydrogen atom
halogen atom
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP50192396A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO1995034559A1 (ja
Inventor
恭司 冨田
勝巳 千葉
茂樹 柏本
厚一郎 柴森
保知 筑木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co Ltd filed Critical Dainippon Pharmaceutical Co Ltd
Publication of JPWO1995034559A1 publication Critical patent/JPWO1995034559A1/ja
Application granted granted Critical
Publication of JP3391796B2 publication Critical patent/JP3391796B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP50192396A 1994-06-14 1995-06-06 新規化合物、その製法および抗腫瘍剤 Expired - Lifetime JP3391796B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
JP15657894 1994-06-14
JP6-156578 1994-06-14
JP6-197921 1994-07-28
JP19792194 1994-07-28
JP6-306914 1994-11-15
JP30691494 1994-11-15
JP33995694 1994-12-28
JP6-339956 1994-12-28
JP8170595 1995-03-13
JP7-81705 1995-03-13
PCT/JP1995/001110 WO1995034559A1 (en) 1994-06-14 1995-06-06 Novel compound, process for producing the same, and antitumor agent

Publications (2)

Publication Number Publication Date
JPWO1995034559A1 JPWO1995034559A1 (ja) 1997-01-28
JP3391796B2 true JP3391796B2 (ja) 2003-03-31

Family

ID=27524935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50192396A Expired - Lifetime JP3391796B2 (ja) 1994-06-14 1995-06-06 新規化合物、その製法および抗腫瘍剤

Country Status (26)

Country Link
US (1) US5817669A (Direct)
EP (1) EP0787726B1 (Direct)
JP (1) JP3391796B2 (Direct)
KR (1) KR100350921B1 (Direct)
CN (1) CN1053668C (Direct)
AT (1) ATE209645T1 (Direct)
AU (1) AU679859B2 (Direct)
BR (1) BR9508037A (Direct)
CA (1) CA2192824C (Direct)
CZ (1) CZ292631B6 (Direct)
DE (1) DE69524251T2 (Direct)
DK (1) DK0787726T3 (Direct)
ES (1) ES2163512T3 (Direct)
FI (1) FI112485B (Direct)
HU (1) HU220072B (Direct)
MX (1) MX9606331A (Direct)
NO (1) NO307255B1 (Direct)
NZ (1) NZ287139A (Direct)
PL (1) PL181867B1 (Direct)
PT (1) PT787726E (Direct)
RO (1) RO117793B1 (Direct)
RU (1) RU2151770C1 (Direct)
SI (1) SI0787726T1 (Direct)
SK (1) SK281341B6 (Direct)
TW (1) TW319769B (Direct)
WO (1) WO1995034559A1 (Direct)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0212864A (pt) * 2001-09-26 2004-08-17 Bayer Pharmaceuticals Corp Derivados de 1,6-naftiridina como antidiabéticos
US6802423B2 (en) * 2002-02-20 2004-10-12 Trans Global Foods, Inc. Disposable food delivery apparatus
EP1610795A4 (en) * 2003-04-07 2007-10-24 Cylene Pharmaceuticals Inc HETEROCYCLIC SUBSTITUTED 1,4-DIHYDRO-4-OXO-1,8-NAPHTHPYRIDINE ANALOGUE
JP4639149B2 (ja) * 2003-09-10 2011-02-23 杏林製薬株式会社 ７−（４−置換−３−シクロプロピルアミノメチル−１−ピロリジニル）キノロンカルボン酸誘導体
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
AU2013201203C1 (en) * 2004-03-15 2015-04-23 Sumitomo Dainippon Pharma Co., Ltd. Sns-595 and methods of using the same
ZA200607248B (en) * 2004-03-15 2009-02-25 Sunesis Pharmaceutical Inc SNS-595 and methods of using the same
BRPI0518164A (pt) * 2004-10-14 2008-11-04 Hoffmann La Roche quinazolinilmetilenotiazolinonas como inibidores de cdk1
CA2583192A1 (en) * 2004-10-14 2006-04-20 F. Hoffmann-La Roche Ag 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity
US7563805B2 (en) 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
RU2420524C2 (ru) * 2005-05-19 2011-06-10 Дайити Санкио Компани, Лимитед Производные три- или тетра-замещенного-3-аминопирролидина
EP1926372A2 (en) * 2005-08-19 2008-06-04 Cylene Pharmaceuticals, Inc. HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF
AU2013219242C1 (en) * 2005-09-02 2016-09-22 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
JP5374153B2 (ja) * 2005-09-02 2013-12-25 サネシス ファーマシューティカルズ， インコーポレイテッド 癌の治療のための（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸を使用する方法
CN104873502A (zh) * 2005-09-02 2015-09-02 逊尼希思制药公司 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
RU2428983C2 (ru) * 2005-09-02 2011-09-20 Санесис Фармасьютикалз, Инк. Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака
AU2006287149B2 (en) * 2005-09-02 2013-05-23 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
BRPI0615838A2 (pt) * 2005-09-14 2011-05-31 Janssen Pharmaceutica Nv 5-oxo-5,8-dihidro-pirido-pirimidinas como inibidores de ofc-fms cinase
CN101505753B (zh) 2006-06-12 2014-05-21 逊尼希思制药公司 治疗癌症的化合物和组合物
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
JP2009545601A (ja) * 2006-08-02 2009-12-24 サネシス ファーマシューティカルズ， インコーポレイテッド （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の組合せ使用
CA2703044C (en) * 2007-10-22 2016-05-10 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
AU2008335772B2 (en) * 2007-12-10 2014-11-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
EP3284745A1 (en) 2008-12-31 2018-02-21 Sunesis Pharmaceuticals, Inc. Composition of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
WO2010099526A1 (en) 2009-02-27 2010-09-02 Sunesis Pharmaceuticals, Inc. Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
SI2712358T1 (sl) 2011-05-13 2017-03-31 Array Biopharma, Inc. Spojine pirolidinil sečnine, pirolidinil tiosečnine in pirolidinil gvanidina kot inhibitorji kinaze trka
CN103497186B (zh) * 2013-09-24 2015-02-25 浙江司太立制药股份有限公司 含有烷氧亚氨基取代的萘啶酮羧酸衍生物及其制备方法
AU2018238079B2 (en) 2017-03-24 2022-03-03 Wakunaga Pharmaceutical Co., Ltd. Novel pyridone carboxylic acid derivative or salt thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988463A (en) * 1974-05-06 1976-10-26 Merck & Co., Inc. Method of preventing metastasis of H. Ep. No. 3
US4384001A (en) * 1978-12-21 1983-05-17 Gosalvez Mario Treatment of tumors with thiazolidine-4-carboxylic acid
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
NZ210847A (en) * 1984-01-26 1988-02-29 Abbott Lab Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions
DE3577089D1 (de) * 1984-01-26 1990-05-17 Abbott Lab Antibakterielle chinolinderivate.
JPS61152682A (ja) * 1984-12-27 1986-07-11 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体、そのエステルおよびその塩
JPS61251667A (ja) * 1985-04-30 1986-11-08 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環化合物
IE60420B1 (en) * 1985-06-13 1994-07-13 Schering Corp Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
EP0226624A1 (en) * 1985-06-14 1987-07-01 The Upjohn Company Cyclopentapyrazole and tetrahydroindazole compounds
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
JP2704428B2 (ja) * 1988-06-15 1998-01-26 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH06233176A (ja) * 1993-01-29 1994-08-19 Sony Corp ビデオカメラ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｙｏｓｈｉｎｏｒｉ Ｙａｍａｓｈｉｔａ，ｅｔ ａｌ．，Ａｎｔｉｔｕｍｏｒ ｑｕｉｎｏｌｏｎｅｓ ｗｉｔｈ ｍａｍｍａｌｉａｎ ｔｏｐｏｉ ｓｏｍｅｒａｓｅ ▲ＩＩ▼ ｍｅｄｉａｔｅｄ ＤＮＡ ｃｌｅａｖａｇｅ ａｃｔｉｖｉｔｙ，Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ，Ｖｏｌ．５２，ｐ．２８１８−２８２２，１９９２

Also Published As

Publication number Publication date
AU679859B2 (en) 1997-07-10
SK281341B6 (sk) 2001-02-12
EP0787726A4 (Direct) 1997-08-06
HK1000495A1 (en) 2002-07-19
PL181867B1 (pl) 2001-09-28
NO965305L (no) 1997-02-04
NZ287139A (en) 1997-07-27
PT787726E (pt) 2002-04-29
CN1053668C (zh) 2000-06-21
NO307255B1 (no) 2000-03-06
KR100350921B1 (ko) 2002-11-18
FI965020A0 (fi) 1996-12-13
EP0787726A1 (en) 1997-08-06
CA2192824A1 (en) 1995-12-21
DE69524251T2 (de) 2002-07-11
DK0787726T3 (da) 2002-02-11
RU2151770C1 (ru) 2000-06-27
FI965020A7 (fi) 1996-12-16
FI112485B (fi) 2003-12-15
CA2192824C (en) 2006-11-07
DE69524251D1 (de) 2002-01-10
SK157496A3 (en) 1997-08-06
HUT75777A (en) 1997-05-28
RO117793B1 (ro) 2002-07-30
US5817669A (en) 1998-10-06
HU9603455D0 (en) 1997-02-28
ATE209645T1 (de) 2001-12-15
CN1158614A (zh) 1997-09-03
ES2163512T3 (es) 2002-02-01
AU2576795A (en) 1996-01-05
WO1995034559A1 (en) 1995-12-21
HU220072B (hu) 2001-10-28
EP0787726B1 (en) 2001-11-28
SI0787726T1 (en) 2002-04-30
PL317726A1 (en) 1997-04-28
MX9606331A (es) 1997-03-29
CZ292631B6 (cs) 2003-11-12
TW319769B (Direct) 1997-11-11
CZ364396A3 (en) 1997-06-11
BR9508037A (pt) 1997-09-16
NO965305D0 (no) 1996-12-11

Similar Documents

Publication Publication Date Title
JP3391796B2 (ja) 新規化合物、その製法および抗腫瘍剤
JPWO1995034559A1 (ja) 新規化合物、その製法および抗腫瘍剤
TWI894413B (zh) 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法
JP4323574B2 (ja) 抗腫瘍剤
JP2546769B2 (ja) キノリン、ナフチリジンおよびピリドベンゾキサジン誘導体
US6316438B1 (en) Fused pyridopyridazine inhibitors of cGMP phosphodiesterase
EA016470B1 (ru) Производные и аналоги n-этилхинолонов и n-этилазахинолонов
HU194561B (en) Process for preparing novel, aminopyrrolidinyl group-substituted 1,8-naphthyridine derivatives and pharmaceuticals comprising such compounds as active substance
FR3008975A1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20130010456A (ko) 신규의 헤테로사이클릭 아크릴아미드 및 약제로서 이의 용도
KR20020094063A (ko) 포스포디에스테라제 저해제로서 유용한 치환된피롤로피리디논 유도체
IE63492B1 (en) A Spiro Compound
KR20160034384A (ko) 인돌 및 피롤의 유도체, 이의 제조 방법 및 이를 함유하는 약제 조성물
JP2025500886A (ja) 大環状ｂｔｋ阻害剤
WO2022199170A1 (zh) 四环类衍生物、其制备方法和其医药上的用途
JP2948660B2 (ja) 新規なピリドンカルボン酸誘導体
CN116600808A (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
WO1992012146A1 (en) Pyridonecarboxylic acid derivative
JP2818198B2 (ja) Ｎ‐（５，６，７，８‐テトラヒドロピリド［２，３‐ｄ］ピリミジン‐６‐イルアルカノイル）グルタミン酸誘導体
JP5079612B2 (ja) 抗腫瘍剤
CN108948003B (zh) 作为mTOR抑制剂的吡嗪并[2,3-c]喹啉-2（1H）-酮类化合物的制备及用途
JPH0873460A (ja) １，８−ナフチリジン化合物および抗腫瘍剤
HK1000495B (en) Novel compound, process for producing the same, and antitumor agent
JP2001181281A (ja) 抗菌剤として有用なキノロン誘導体
JPH1112278A (ja) ピリドンカルボン酸誘導体、そのエステルまたはこれらの塩

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090124

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100124

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110124

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120124

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130124

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140124

Year of fee payment: 11

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term